Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 26, 2004
"We experienced impressive growth across all our businesses and regions," said Jim Tobin, President and Chief Executive Officer.
-
Jul 22, 2004
ATLAS is the first clinical trial using Boston Scientific's new Liberté coronary stent as a platform for its paclitaxel-eluting coronary stent system.
-
Jul 21, 2004
A live webcast and replay of the July 26 conference call will be available.
-
Jul 16, 2004
"Patient safety continues to be our highest priority," said Jim Tobin, President and Chief Executive Officer.
-
Jul 8, 2004
Prospective, multi-center, randomized study designed to evaluate the benefits of filter-based embolic protection during primary percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI).
-
Jul 2, 2004
The voluntary recall does not affect patients who have already received a TAXUS stent.
-
Jun 25, 2004
Company plans to use the proceeds to repay commercial paper borrowings and for other general corporate purposes.
-
Jun 22, 2004
Company announces launch of a public offering of $500 million aggregate principal amount of senior notes.
-
Jun 8, 2004
A live webcast and replay of the June 9th conference session will be available.
-
Jun 3, 2004
Company estimates that its share of the U.S. drug-eluting stent market - as of May 31st - continues to be in excess of 70 percent, on a reorder basis.